This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Eguchi, K.
Right arrow Articles by Ueda, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eguchi, K.
Right arrow Articles by Ueda, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3391-3398, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00972-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Pharmacodynamics of SMP-601 (PTZ601) against Vancomycin-Resistant Enterococcus faecium and Methicillin-Resistant Staphylococcus aureus in Neutropenic Murine Thigh Infection Models{triangledown}

Ken Eguchi,* Katsunori Kanazawa, Yoshiro Eriguchi, and Yutaka Ueda

Dainippon Sumitomo Pharma Co., Ltd., Drug Research Division, Osaka, Japan

Received 22 July 2008/ Returned for modification 17 October 2008/ Accepted 27 May 2009

SMP-601 (also known as PTZ601, PZ-601, or SM-216601) is a novel parenteral carbapenem with potent activity against multidrug-resistant gram-positive pathogens, including vancomycin-resistant Enterococcus faecium (VREF) and methicillin-resistant Staphylococcus aureus (MRSA). The pharmacodynamics of SMP-601 against VREF and MRSA were investigated in neutropenic murine thigh infection models. The percentage of the dosing interval that the unbound SMP-601 concentration exceeded the MIC (f%T>MIC) was the pharmacokinetic-pharmacodynamic parameter that correlated most closely with efficacy with R2 values of 0.81 to 0.84 for two strains of VREF and 0.92 to 0.93 for two strains of MRSA, whereas the R2 values for the area under the concentration-time curve from 0 to 24 h divided by the MIC were 0.12 to 0.89, and the R2 values for the peak level divided by the MIC were 0 to 0.22. The f%T>MIC levels required for static or killing efficacy against two strains of VREF (9 to 19%) apparently were lower than those against two strains of MRSA (23 to 37%). These results suggested that SMP-601 showed time-dependent in vivo efficacy against VREF and MRSA, and SMP-601 had a sufficient therapeutic effect against VREF infections at lower exposure conditions compared to those for with MRSA infections.

* Corresponding author. Mailing address: Discovery Pharmacology III, Pharmacology Research Laboratories, Drug Research Division, Dainippon Sumitomo Pharma Co., Ltd., 3-1-98, Kasugade Naka, Konohana-ku, Osaka 554-0022, Japan. Phone: 81-6-6466-5271. Fax: 81-6-6466-5491. E-mail: ken-eguchi{at}ds-pharma.co.jp

{triangledown} Published ahead of print on 1 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3391-3398, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00972-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»